Form 4: United Therapeutics CFO Executes Stock Option Plan

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• CFO James Edgemond exercised 10,000 stock options at a strike price of $135.42.
• Following the exercise, the reporting person sold all 10,000 shares in multiple tranches on April 30, 2026.
• The sales were executed at weighted average prices ranging from $569.24 to $578.76 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan established on October 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive financial management.

Positives

• The transaction was executed under a pre-established Rule 10b5-1 plan, indicating the sales were not based on non-public information.
• The exercise of options demonstrates the executive's participation in the company's long-term equity incentive program.

Negatives

• The executive reduced their direct beneficial ownership of common stock by 10,000 shares through this exercise and sale cycle.

Risks

• None identified; this is a routine disclosure of executive equity transactions.

Future Outlook

No forward-looking guidance provided; this is a disclosure of past insider transactions.

Industry Context

StockSavvy.ai notes that routine 10b5-1 trading plan executions by C-suite executives are standard corporate practice and generally do not signal a change in company fundamentals or management sentiment.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to sell shares while avoiding potential insider trading liability.
• The transaction volume is consistent with typical executive compensation and liquidity management practices in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was conducted via a pre-arranged plan.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, CFO, Stock Options, 10b5-1